MENU
CVAC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
CureVac (CVAC) Ownership - Who owns CureVac?
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people... Show more
Profile
Industry
N/A
Address
Friedrich-Miescher-Strasse 15
Phone
+49 707198830
Employees
1049
Web
https://www.curevac.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.01B
P/E Ratio
4.90
Total Cash
554.92M
Projected Growth
N/A
Total Debt
40.13M
Revenue
543.28M
Risk (Beta)
1.79
Dividend Yield
N/A
Total Cash/Share
2.46
Total Debt/Equity
N/A
Revenue/Share
2.64 USD as % of share price
Fundamentals
CVAC
Capitalization
1.01B
P/E Ratio
4.90
Risk (Beta)
1.79
Dividend Yield
N/A
Total Cash
555M
Total Cash/Share
2.46
Total Debt
40.1M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
2.64%
Revenue
543M
ROE
N/A
Book Value
725M
P/B Ratio
1.37
Cash Flow
N/A
Earnings
0.48
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
26.9M
Current Ratio
6.20
Current Revenue Per Employee
449001.80
Dividends Per Share - Security
N/A
EBITDA
166M
Float
N/A
Float - Current
N/A
Gross Income Margin
95.56
Revenue To Assets
12.76
Shares Held By Institutions
51.5M
Shares Outstanding - Current
225M
Total Liabilities
129M
Total Volume MTD
N/A
Value
N/A
Gain YTD
30.205
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company developing tumour immunotherapy
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
Friedrich-Miescher-Strasse 15
Phone
+49 707198830
Employees
1049
Web
https://www.curevac.com